8-K: Telomir Pharmaceuticals' Telomir-1 Shows Significant Promise in Wilsons Disease Preclinical Study

Telomir Pharmaceuticals, Inc. announced new preclinical data demonstrating its lead small molecule candidate, Telomir-1, significantly improved neurological, behavioral, liver, and kidney outcomes in an animal model of Wilsons disease.

Summary

• Telomir Pharmaceuticals, Inc. (NASDAQ:TELO) released new preclinical data for its lead small molecule candidate, Telomir-1, in a clinically relevant animal model of Wilsons disease (ATP7B C271X -/zebrafish).
• Wilsons disease is a rare, life-threatening genetic disorder caused by ATP7B gene mutations leading to excess copper accumulation, primarily in the liver and brain, causing inflammation, tissue damage, and organ dysfunction.
• Telomir-1 demonstrated dose-dependent and statistically significant reversal of multiple disease-relevant endpoints in the Wilsons disease model.
• Key improvements included up to a 4to 5-fold reduction in episodic tremor events, normalization of swim distance, swim velocity, and exploratory behavior, and reversal of ataxia-like behaviors.
• The study also showed approximately 50% reduction in copper accumulation in dry liver tissue and significant, dose-dependent improvement in liver and kidney histopathology, with scores reduced to near-normal levels.
• Telomir-1 normalized ALT, AST, and bilirubin levels, which are critical markers of liver health, indicating protection of liver function and improved detoxification capacity.
• Improved survival was observed under high copper exposure conditions in the treated animals.
• These findings support Telomir-1's potential as a disease-modifying treatment for both hepatic and neurological manifestations of copper toxicity.
• Telomir Pharmaceuticals is advancing Telomir-1 toward an Investigational New Drug (IND) submission in a rare disease indication by year-end 2025, with human clinical trials planned for the first half of 2026.

Sentiment

Score: 8

Explanation: The preclinical data for Telomir-1 in Wilsons disease is highly positive, showing significant and dose-dependent improvements across multiple critical disease markers. This strong scientific validation for a lead candidate targeting a rare, life-threatening condition with unmet needs indicates substantial future potential for the company.

Positives

• Telomir-1 demonstrated dose-dependent and statistically significant reversal of multiple disease-relevant endpoints in a Wilsons disease animal model.
• Observed up to a 4to 5-fold reduction in episodic tremor events.
• Achieved normalization of swim distance, swim velocity, and exploratory behavior.
• Reversed ataxia-like behaviors, including abnormal body bends and turn angles.
• Resulted in approximately 50% reduction in copper accumulation in dry liver tissue.
• Showed significant and dose-dependent improvement in liver and kidney histopathology, reducing scores to near-normal levels.
• Normalized ALT, AST, and bilirubin levels, indicating restored liver function and improved detoxification capacity.
• Improved survival rates under high copper exposure conditions.
• The findings support Telomir-1's potential as a disease-modifying treatment for both liver and neurological symptoms of copper toxicity.
• The company is operating at full speed, targeting an IND submission by year-end 2025 and human clinical trials in the first half of 2026.

Future Outlook

Telomir Pharmaceuticals is operating at full speed and plans to submit an Investigational New Drug (IND) application for Telomir-1 in a rare disease indication by year-end 2025, with human clinical trials projected to commence in the first half of 2026.

Management Comments

• Telomir Pharmaceuticals is operating at full speed and currently advancing Telomir-1 toward an IND submission in a rare disease indication by year-end, with human clinical trials planned for the first half of 2026.

Industry Context

Wilsons disease is a rare and potentially life-threatening genetic disorder with significant unmet medical needs. Current therapies, such as lifelong copper chelation or liver transplantation, are burdensome and highlight the demand for safer, disease-modifying treatments. Telomir-1's preclinical success in targeting both hepatic and neurological manifestations of copper toxicity positions it as a promising candidate in this underserved therapeutic area.

Comparison to Industry Standards

• The document highlights that current therapies for Wilsons disease involve lifelong copper chelation or liver transplantation, underscoring a significant unmet need for safer, disease-modifying treatments.
• Telomir-1's preclinical results, demonstrating reversal of neurological dysfunction, liver and kidney damage, copper accumulation, and mortality in a clinically relevant genetic model, suggest a potential for a disease-modifying approach that could surpass the symptomatic management offered by existing treatments.

Stakeholder Impact

• Shareholders: Positive news regarding a lead drug candidate's strong preclinical performance could lead to increased investor confidence and potential stock appreciation.
• Patients with Wilsons disease: Offers hope for a new, potentially disease-modifying treatment option that could improve quality of life and survival compared to current therapies.
• Medical community: Provides new scientific data supporting a novel therapeutic approach for Wilsons disease, potentially influencing future treatment paradigms.

Next Steps

• Advance Telomir-1 toward an Investigational New Drug (IND) submission in a rare disease indication by year-end 2025.
• Initiate human clinical trials for Telomir-1 in the first half of 2026.

Key Dates

Recommendation

Keywords

Telomir Pharmaceuticals, Telomir-1, Wilsons disease, preclinical data, rare disease, genetic disorder, copper accumulation, neurological dysfunction, liver disease, kidney disease, ATP7B, small molecule, drug development, biotechnology, IND submission, clinical trials